<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON
NASDAQ INTERDEALER QUOTATION SYSTEM
Filed pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 and Rule 13a-17
or 15d-17 thereunder
SOMATIX THERAPY CORPORATION
____________________________________________________________
(Exact name of issuer as specified in charter)
950 MARINA VILLAGE PARKWAY, SUITE 100, ALAMEDA, CA 94501-1034
____________________________________________________________
(Address of principal executive offices)
Issuer's telephone number, including area code (510) 748-3000
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security COMMON STOCK
2. Number of shares outstanding before the change 18,112,056
3. Number of shares outstanding after the change 24,909,587
4. Effective date of change JUNE 28, 1995
5. Method of change PRIVATE PLACEMENT
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Give brief description of the transaction STOCK ISSUANCE IN CONNECTION WITH
PRIVATE PLACEMENT OF COMMON STOCK, CONVERTIBLE RESET PREFERRED STOCK, AND
WARRANTS TO PURCHASE COMMON STOCK
II. CHANGE IN NAME OF ISSUER
1. Name prior to change N/A
2. Name after change N/A
3. Effective date of charter amendment changing name N/A
4. Date of shareholder approval of change, if required N/A
Date JULY 10, 1995 /S/ MARK N.K. BAGNALL
------------------------------------------
Mark N.K. Bagnall, Chief Financial Officer
